ADC Therapeutics SA 公布了其关键性Lotis-5三期确证临床试验的数据。该研究旨在评估Zynlonta®与利妥昔单抗联合疗法，用于治疗复发或难治性弥漫大B细胞淋巴瘤患者。
试验结果的揭晓，标志着该公司核心产品管线的一项重要进展。弥漫大B细胞淋巴瘤是一种侵袭性非霍奇金淋巴瘤，对于初始治疗无效或治疗后复发的患者而言，临床需求远未得到满足。此次三期试验的数据，将为Zynlonta®在此适应症上的应用前景提供关键依据。
Zynlonta®是一种靶向CD19的抗体偶联药物。它与广泛使用的抗CD20单抗利妥昔单抗的联合应用，代表了针对这一难治性疾病的一种创新治疗策略。Lotis-5试验的结果，预计将影响未来的治疗格局与监管审评路径。
公司此次信息发布，聚焦于临床数据本身。投资者与行业观察者正密切关注这些结果，以评估其对该药物商业潜力及ADC Therapeutics未来发展的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.